Patents by Inventor David L. Levens

David L. Levens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fuse binding protein and method for inhibiting expression of fuse binding protein
    Patent number: 5734016
    Abstract: The Far Upstream Element (FUSE) of the human c-myc gene stimulates expression in undifferentiated cells. A FUSE binding protein (FBP), also referred to as DROME (DNA-binding regulator of c-myc expression), is active in undifferentiated but not differentiated cell extracts. Cloned FBP exhibits the same DNA-binding specificity as the purified human protein and can trans-activate in a FUSE dependent manner. Sequence-specific binding to the FUSE oligonucleotide requires at least two copies of a repeat-helix unit which defines a new DNA-binding motif. Expression of FBP mRNA declined in parallel with decreased FUSE binding activity upon differentiation suggesting transcriptional regulation of FBP.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: March 31, 1998
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: David L. Levens, Robert C. Duncan, Mark I. Avigan
  • FUSE binding protein and cDNA therefor
    Patent number: 5580760
    Abstract: The Far Upstream Element (FUSE) of the human c-myc gene, stimulates expression in undifferentiated cells. A FUSE binding protein (FBP), also referred to as DROME (DNA-binding regulator of c-myc expression), is active in undifferentiated but not differentiated cell extracts. Cloned FBP exhibits the same DNA-binding specificity as the purified human protein and can trans-activate in a FUSE dependent manner. Sequence-specific binding to the FUSE oligonucleotide required at least two copies of a repeat-helix unit which defines a new DNA-binding motif. Expression of FBP mRNA declined in parallel with decreased FUSE binding activity upon differentiation suggesting transcriptional regulation of FBP. Features were identified in clones which suggested FBP is also regulated by RNA processing, translation and post-translational mechanisms.
    Type: Grant
    Filed: February 22, 1993
    Date of Patent: December 3, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: David L. Levens, Robert C. Duncan, Mark I. Avigan